|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
3
|
Chlorthalidone
|
Chronic bronchitis
|
1395058
|
255841
|
Chlorthalidone & Chronic bronchitis
|
## Chronograph ##

## Basic demographioc table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
117
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
731
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
65
|
56
|
Sex
|
gender = FEMALE
|
593
|
59
|
Sex
|
gender = FEMALE
|
406
|
56
|
Sex
|
gender = FEMALE
|
576
|
58
|
|
|
gender = MALE
|
52
|
44
|
|
gender = MALE
|
407
|
41
|
|
gender = MALE
|
325
|
44
|
|
gender = MALE
|
424
|
42
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
0
|
0
|
|
(20,30]
|
3
|
0
|
|
(20,30]
|
4
|
1
|
|
(20,30]
|
10
|
1
|
|
|
(30,40]
|
6
|
5
|
|
(30,40]
|
29
|
3
|
|
(30,40]
|
13
|
2
|
|
(30,40]
|
21
|
2
|
|
|
(40,50]
|
4
|
3
|
|
(40,50]
|
41
|
4
|
|
(40,50]
|
31
|
4
|
|
(40,50]
|
27
|
3
|
|
|
(50,60]
|
12
|
10
|
|
(50,60]
|
72
|
7
|
|
(50,60]
|
32
|
4
|
|
(50,60]
|
56
|
6
|
|
|
(60,70]
|
28
|
24
|
|
(60,70]
|
232
|
23
|
|
(60,70]
|
164
|
22
|
|
(60,70]
|
247
|
25
|
|
|
(70,80]
|
40
|
34
|
|
(70,80]
|
337
|
34
|
|
(70,80]
|
249
|
34
|
|
(70,80]
|
361
|
36
|
|
|
(80,90]
|
21
|
18
|
|
(80,90]
|
225
|
22
|
|
(80,90]
|
192
|
26
|
|
(80,90]
|
231
|
23
|
|
|
(90,110]
|
6
|
5
|
|
(90,110]
|
61
|
6
|
|
(90,110]
|
46
|
6
|
|
(90,110]
|
47
|
5
|
|
|
Median
|
72
|
IQR=(66, 80)
|
|
Median
|
74
|
IQR=(68, 82)
|
|
Median
|
75
|
IQR=(68, 83)
|
|
Median
|
74
|
IQR=(68, 82)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 117)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 117)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.6
|
1.4
|
-0.08
|
|
25 - 29
|
0
|
0.3
|
0.08
|
Visual system disorder
|
46.2
|
36.6
|
-0.19
|
|
30 - 34
|
0.9
|
0.7
|
-0.02
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
4.3
|
1.7
|
-0.15
|
Atrial fibrillation
|
41.9
|
26.6
|
-0.33
|
|
40 - 44
|
0.9
|
1.7
|
0.08
|
Cerebrovascular disease
|
17.1
|
10.0
|
-0.21
|
|
45 - 49
|
2.6
|
2.4
|
-0.01
|
Coronary arteriosclerosis
|
45.3
|
30.4
|
-0.31
|
|
50 - 54
|
3.4
|
3.5
|
0.00
|
Heart disease
|
82.9
|
56.9
|
-0.59
|
|
55 - 59
|
4.3
|
3.6
|
-0.03
|
Heart failure
|
44.4
|
24.5
|
-0.43
|
|
60 - 64
|
5.1
|
3.9
|
-0.06
|
Ischemic heart disease
|
16.2
|
13.5
|
-0.08
|
|
65 - 69
|
17.1
|
15.4
|
-0.05
|
Peripheral vascular disease
|
42.7
|
26.2
|
-0.35
|
|
70 - 74
|
17.1
|
17.4
|
0.01
|
Pulmonary embolism
|
3.4
|
2.8
|
-0.04
|
|
75 - 79
|
17.1
|
17.4
|
0.01
|
Venous thrombosis
|
9.4
|
6.6
|
-0.10
|
|
80 - 84
|
12.0
|
14.1
|
0.06
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
10.3
|
10.2
|
0.00
|
Hematologic neoplasm
|
9.4
|
7.2
|
-0.08
|
|
90 - 94
|
1.7
|
4.5
|
0.16
|
Malignant lymphoma
|
5.1
|
2.9
|
-0.11
|
|
95 - 99
|
3.4
|
2.3
|
-0.07
|
Malignant neoplasm of anorectum
|
0.9
|
1.1
|
0.02
|
|
100 - 104
|
0
|
0.9
|
0.13
|
Malignant neoplastic disease
|
40.2
|
26.0
|
-0.30
|
|
Gender: female
|
55.6
|
59.3
|
0.08
|
Malignant tumor of breast
|
6.8
|
3.9
|
-0.13
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
6.8
|
2.6
|
-0.20
|
|
Acute respiratory disease
|
28.2
|
20.3
|
-0.19
|
Malignant tumor of lung
|
3.4
|
2.0
|
-0.09
|
|
Attention deficit hyperactivity disorder
|
1.7
|
0.7
|
-0.09
|
Malignant tumor of urinary bladder
|
3.4
|
2.8
|
-0.04
|
|
Chronic liver disease
|
5.1
|
2.2
|
-0.16
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
17.1
|
9.6
|
-0.22
|
Agents acting on the renin-angiotensin system
|
77.8
|
73.8
|
-0.09
|
|
Crohn’s disease
|
0
|
0.6
|
0.11
|
Antibacterials for systemic use
|
62.4
|
47.6
|
-0.30
|
|
Dementia
|
17.9
|
12.3
|
-0.16
|
Antidepressants
|
70.1
|
58.7
|
-0.24
|
|
Depressive disorder
|
24.8
|
10.8
|
-0.37
|
Antiepileptics
|
43.6
|
36.4
|
-0.15
|
|
Diabetes mellitus
|
75.2
|
52.4
|
-0.49
|
Antiinflammatory and antirheumatic products
|
39.3
|
34.8
|
-0.09
|
|
Gastroesophageal reflux disease
|
26.5
|
14.1
|
-0.31
|
Antineoplastic agents
|
17.1
|
10.9
|
-0.18
|
|
Gastrointestinal hemorrhage
|
10.3
|
4.1
|
-0.24
|
Antipsoriatics
|
0.9
|
0.8
|
-0.01
|
|
Human immunodeficiency virus infection
|
0.9
|
0.8
|
-0.01
|
Antithrombotic agents
|
59.0
|
46.7
|
-0.25
|
|
Hyperlipidemia
|
39.3
|
23.7
|
-0.34
|
Beta blocking agents
|
74.4
|
77.5
|
0.07
|
|
Hypertensive disorder
|
14.5
|
4.4
|
-0.35
|
Calcium channel blockers
|
59.0
|
54.6
|
-0.09
|
|
Lesion of liver
|
7.7
|
2.7
|
-0.23
|
Diuretics
|
74.4
|
68.9
|
-0.12
|
|
Obesity
|
12.0
|
5.5
|
-0.23
|
Drugs for acid related disorders
|
65.0
|
45.4
|
-0.40
|
|
Osteoarthritis
|
61.5
|
38.3
|
-0.48
|
Drugs for obstructive airway diseases
|
51.3
|
39.8
|
-0.23
|
|
Pneumonia
|
6.8
|
5.2
|
-0.07
|
Drugs used in diabetes
|
66.7
|
58.2
|
-0.18
|
|
Psoriasis
|
3.4
|
1.5
|
-0.12
|
Immunosuppressants
|
4.3
|
4.7
|
0.02
|
|
Renal impairment
|
41.0
|
22.5
|
-0.41
|
Lipid modifying agents
|
81.2
|
76.2
|
-0.12
|
|
Rheumatoid arthritis
|
9.4
|
5.9
|
-0.13
|
Opioids
|
40.2
|
31.2
|
-0.19
|
|
Schizophrenia
|
6.8
|
6.0
|
-0.03
|
Psycholeptics
|
61.5
|
50.9
|
-0.22
|
|
Ulcerative colitis
|
0
|
0.4
|
0.09
|
Psychostimulants, agents used for adhd and nootropics
|
16.2
|
13.8
|
-0.07
|
|
Urinary tract infectious disease
|
27.4
|
19.9
|
-0.18
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 731)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 731)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.1
|
2.3
|
0.02
|
|
25 - 29
|
0.4
|
0.5
|
0.01
|
Visual system disorder
|
51.6
|
36.7
|
-0.30
|
|
30 - 34
|
0.7
|
1.0
|
0.03
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
0.8
|
1.2
|
0.04
|
Atrial fibrillation
|
45.4
|
27.3
|
-0.38
|
|
40 - 44
|
1.2
|
1.4
|
0.01
|
Cerebrovascular disease
|
17.1
|
8.0
|
-0.28
|
|
45 - 49
|
2.7
|
1.3
|
-0.10
|
Coronary arteriosclerosis
|
48.0
|
31.7
|
-0.34
|
|
50 - 54
|
2.9
|
2.4
|
-0.03
|
Heart disease
|
83.0
|
56.9
|
-0.59
|
|
55 - 59
|
1.9
|
2.8
|
0.06
|
Heart failure
|
43.2
|
23.0
|
-0.44
|
|
60 - 64
|
3.4
|
4.3
|
0.05
|
Ischemic heart disease
|
24.9
|
11.8
|
-0.34
|
|
65 - 69
|
14.8
|
16.7
|
0.05
|
Peripheral vascular disease
|
47.1
|
25.1
|
-0.47
|
|
70 - 74
|
19.6
|
21.7
|
0.05
|
Pulmonary embolism
|
4.5
|
2.2
|
-0.13
|
|
75 - 79
|
15.7
|
16.4
|
0.02
|
Venous thrombosis
|
11.6
|
6.1
|
-0.20
|
|
80 - 84
|
17.0
|
14.1
|
-0.08
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
10.4
|
9.6
|
-0.03
|
Hematologic neoplasm
|
15.3
|
10.2
|
-0.15
|
|
90 - 94
|
4.9
|
4.2
|
-0.03
|
Malignant lymphoma
|
6.2
|
4.6
|
-0.07
|
|
95 - 99
|
2.7
|
2.0
|
-0.05
|
Malignant neoplasm of anorectum
|
3.8
|
1.5
|
-0.15
|
|
100 - 104
|
0.8
|
0.4
|
-0.05
|
Malignant neoplastic disease
|
44.6
|
28.8
|
-0.33
|
|
Gender: female
|
55.5
|
57.6
|
0.04
|
Malignant tumor of breast
|
6.7
|
2.5
|
-0.20
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
6.3
|
3.8
|
-0.11
|
|
Acute respiratory disease
|
37.6
|
20.9
|
-0.37
|
Malignant tumor of lung
|
8.2
|
4.4
|
-0.16
|
|
Attention deficit hyperactivity disorder
|
0.4
|
0.4
|
0.00
|
Malignant tumor of urinary bladder
|
5.2
|
2.7
|
-0.13
|
|
Chronic liver disease
|
3.0
|
2.2
|
-0.05
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
23.8
|
10.1
|
-0.37
|
Agents acting on the renin-angiotensin system
|
43.6
|
0
|
-1.24
|
|
Crohn’s disease
|
0.7
|
0.7
|
0.00
|
Antibacterials for systemic use
|
36.7
|
0
|
-1.08
|
|
Dementia
|
18.9
|
10.9
|
-0.23
|
Antidepressants
|
42.3
|
0
|
-1.21
|
|
Depressive disorder
|
13.7
|
6.9
|
-0.22
|
Antiepileptics
|
26.4
|
0
|
-0.85
|
|
Diabetes mellitus
|
71.8
|
48.8
|
-0.48
|
Antiinflammatory and antirheumatic products
|
22.7
|
0
|
-0.77
|
|
Gastroesophageal reflux disease
|
22.7
|
14.4
|
-0.21
|
Antineoplastic agents
|
15.5
|
0
|
-0.60
|
|
Gastrointestinal hemorrhage
|
9.7
|
7.2
|
-0.09
|
Antipsoriatics
|
0.8
|
0
|
-0.13
|
|
Human immunodeficiency virus infection
|
0.8
|
0.4
|
-0.05
|
Antithrombotic agents
|
39.0
|
0
|
-1.13
|
|
Hyperlipidemia
|
36.3
|
25.2
|
-0.24
|
Beta blocking agents
|
40.2
|
0
|
-1.16
|
|
Hypertensive disorder
|
6.2
|
4.8
|
-0.06
|
Calcium channel blockers
|
32.4
|
0
|
-0.98
|
|
Lesion of liver
|
4.2
|
2.4
|
-0.10
|
Diuretics
|
43.1
|
0
|
-1.23
|
|
Obesity
|
10.1
|
4.1
|
-0.24
|
Drugs for acid related disorders
|
31.7
|
0
|
-0.96
|
|
Osteoarthritis
|
56.8
|
37.6
|
-0.39
|
Drugs for obstructive airway diseases
|
34.6
|
0
|
-1.03
|
|
Pneumonia
|
9.7
|
5.1
|
-0.18
|
Drugs used in diabetes
|
37.3
|
0
|
-1.09
|
|
Psoriasis
|
3.1
|
1.0
|
-0.15
|
Immunosuppressants
|
3.8
|
0
|
-0.28
|
|
Renal impairment
|
36.9
|
22.7
|
-0.32
|
Lipid modifying agents
|
46.5
|
0
|
-1.32
|
|
Rheumatoid arthritis
|
9.4
|
7.0
|
-0.09
|
Opioids
|
27.9
|
0
|
-0.88
|
|
Schizophrenia
|
8.9
|
3.7
|
-0.21
|
Psycholeptics
|
40.6
|
0
|
-1.17
|
|
Ulcerative colitis
|
0.7
|
0.5
|
-0.02
|
Psychostimulants, agents used for adhd and nootropics
|
11.9
|
0
|
-0.52
|
|
Urinary tract infectious disease
|
29.5
|
20.0
|
-0.22
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 731)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 731)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.1
|
2.3
|
0.02
|
|
25 - 29
|
0.4
|
0.5
|
0.01
|
Visual system disorder
|
51.6
|
36.7
|
-0.30
|
|
30 - 34
|
0.7
|
1.0
|
0.03
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
0.8
|
1.2
|
0.04
|
Atrial fibrillation
|
45.4
|
27.3
|
-0.38
|
|
40 - 44
|
1.2
|
1.4
|
0.01
|
Cerebrovascular disease
|
17.1
|
8.0
|
-0.28
|
|
45 - 49
|
2.7
|
1.3
|
-0.10
|
Coronary arteriosclerosis
|
48.0
|
31.7
|
-0.34
|
|
50 - 54
|
2.9
|
2.4
|
-0.03
|
Heart disease
|
83.0
|
56.9
|
-0.59
|
|
55 - 59
|
1.9
|
2.8
|
0.06
|
Heart failure
|
43.2
|
23.0
|
-0.44
|
|
60 - 64
|
3.4
|
4.3
|
0.05
|
Ischemic heart disease
|
24.9
|
11.8
|
-0.34
|
|
65 - 69
|
14.8
|
16.7
|
0.05
|
Peripheral vascular disease
|
47.1
|
25.1
|
-0.47
|
|
70 - 74
|
19.6
|
21.7
|
0.05
|
Pulmonary embolism
|
4.5
|
2.2
|
-0.13
|
|
75 - 79
|
15.7
|
16.4
|
0.02
|
Venous thrombosis
|
11.6
|
6.1
|
-0.20
|
|
80 - 84
|
17.0
|
14.1
|
-0.08
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
10.4
|
9.6
|
-0.03
|
Hematologic neoplasm
|
15.3
|
10.2
|
-0.15
|
|
90 - 94
|
4.9
|
4.2
|
-0.03
|
Malignant lymphoma
|
6.2
|
4.6
|
-0.07
|
|
95 - 99
|
2.7
|
2.0
|
-0.05
|
Malignant neoplasm of anorectum
|
3.8
|
1.5
|
-0.15
|
|
100 - 104
|
0.8
|
0.4
|
-0.05
|
Malignant neoplastic disease
|
44.6
|
28.8
|
-0.33
|
|
Gender: female
|
55.5
|
57.6
|
0.04
|
Malignant tumor of breast
|
6.7
|
2.5
|
-0.20
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
6.3
|
3.8
|
-0.11
|
|
Acute respiratory disease
|
37.6
|
20.9
|
-0.37
|
Malignant tumor of lung
|
8.2
|
4.4
|
-0.16
|
|
Attention deficit hyperactivity disorder
|
0.4
|
0.4
|
0.00
|
Malignant tumor of urinary bladder
|
5.2
|
2.7
|
-0.13
|
|
Chronic liver disease
|
3.0
|
2.2
|
-0.05
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
23.8
|
10.1
|
-0.37
|
Agents acting on the renin-angiotensin system
|
43.6
|
0
|
-1.24
|
|
Crohn’s disease
|
0.7
|
0.7
|
0.00
|
Antibacterials for systemic use
|
36.7
|
0
|
-1.08
|
|
Dementia
|
18.9
|
10.9
|
-0.23
|
Antidepressants
|
42.3
|
0
|
-1.21
|
|
Depressive disorder
|
13.7
|
6.9
|
-0.22
|
Antiepileptics
|
26.4
|
0
|
-0.85
|
|
Diabetes mellitus
|
71.8
|
48.8
|
-0.48
|
Antiinflammatory and antirheumatic products
|
22.7
|
0
|
-0.77
|
|
Gastroesophageal reflux disease
|
22.7
|
14.4
|
-0.21
|
Antineoplastic agents
|
15.5
|
0
|
-0.60
|
|
Gastrointestinal hemorrhage
|
9.7
|
7.2
|
-0.09
|
Antipsoriatics
|
0.8
|
0
|
-0.13
|
|
Human immunodeficiency virus infection
|
0.8
|
0.4
|
-0.05
|
Antithrombotic agents
|
39.0
|
0
|
-1.13
|
|
Hyperlipidemia
|
36.3
|
25.2
|
-0.24
|
Beta blocking agents
|
40.2
|
0
|
-1.16
|
|
Hypertensive disorder
|
6.2
|
4.8
|
-0.06
|
Calcium channel blockers
|
32.4
|
0
|
-0.98
|
|
Lesion of liver
|
4.2
|
2.4
|
-0.10
|
Diuretics
|
43.1
|
0
|
-1.23
|
|
Obesity
|
10.1
|
4.1
|
-0.24
|
Drugs for acid related disorders
|
31.7
|
0
|
-0.96
|
|
Osteoarthritis
|
56.8
|
37.6
|
-0.39
|
Drugs for obstructive airway diseases
|
34.6
|
0
|
-1.03
|
|
Pneumonia
|
9.7
|
5.1
|
-0.18
|
Drugs used in diabetes
|
37.3
|
0
|
-1.09
|
|
Psoriasis
|
3.1
|
1.0
|
-0.15
|
Immunosuppressants
|
3.8
|
0
|
-0.28
|
|
Renal impairment
|
36.9
|
22.7
|
-0.32
|
Lipid modifying agents
|
46.5
|
0
|
-1.32
|
|
Rheumatoid arthritis
|
9.4
|
7.0
|
-0.09
|
Opioids
|
27.9
|
0
|
-0.88
|
|
Schizophrenia
|
8.9
|
3.7
|
-0.21
|
Psycholeptics
|
40.6
|
0
|
-1.17
|
|
Ulcerative colitis
|
0.7
|
0.5
|
-0.02
|
Psychostimulants, agents used for adhd and nootropics
|
11.9
|
0
|
-0.52
|
|
Urinary tract infectious disease
|
29.5
|
20.0
|
-0.22
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
beta blocking agents
|
174
|
|
antithrombotic agents
|
138
|
|
cardiovascular system
|
116
|
|
alimentary tract and metabolism
|
112
|
|
nervous system
|
111
|
|
antiepileptics
|
102
|
|
respiratory system
|
97
|
|
lipid modifying agents
|
95
|
|
lipid modifying agents, plain
|
95
|
|
agents acting on the renin-angiotensin system
|
91
|
|
diuretics
|
87
|
|
psychoanaleptics
|
87
|
|
analgesics
|
86
|
|
hmg coa reductase inhibitors
|
85
|
|
antihistamines for systemic use
|
84
|
|
blood and blood forming organs
|
83
|
|
antidepressants
|
82
|
|
sensory organs
|
81
|
|
ophthalmologicals
|
80
|
|
all other therapeutic products
|
78
|
|
drugs used in diabetes
|
78
|
|
ace inhibitors, plain
|
77
|
|
ace inhibitors, plain
|
77
|
|
antiinfectives for systemic use
|
77
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
77
|
|
cond_180_days
|
n_180_days
|
|
inflammation of specific body systems
|
99
|
|
arthropathy
|
97
|
|
heart disease
|
97
|
|
inflammation of specific body organs
|
92
|
|
pain
|
89
|
|
diabetes mellitus
|
88
|
|
pain finding at anatomical site
|
87
|
|
measurement finding outside reference range
|
83
|
|
type 2 diabetes mellitus
|
81
|
|
vascular disorder
|
81
|
|
pain of truncal structure
|
76
|
|
soft tissue lesion
|
74
|
|
degenerative disorder of musculoskeletal system
|
72
|
|
osteoarthritis
|
72
|
|
cardiac arrhythmia
|
68
|
|
neoplastic disease
|
66
|
|
musculoskeletal and connective tissue disorder
|
65
|
|
abnormal blood cell count
|
64
|
|
structural disorder of heart
|
64
|
|
measurement finding below reference range
|
63
|
|
anemia
|
61
|
|
arteriosclerotic vascular disease
|
61
|
|
cytopenia
|
61
|
|
erythropenia
|
61
|
|
hemoglobin level outside reference range
|
61
|